Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
ESMO Breast 2023
;
May is #BladderCancerAwarenessMonth 📣
@drenriquegrande discusses implications of the findings from the EV-302 trial (NCT04223856) of #enfortumab vedotin, an #ADC & #pembrolizumab in patients with locally advanced or metastatic #urothelialcancer 🔦
👉
Will enfortumab vedotin and pembrolizumab be the new SOC in urothelial cancer?
Enrique Grande, MD, PhD, MD Anderson Cancer Centre Madrid, Madrid, Spain, discusses the implications of the findings ...
ow.ly
We’re looking forward to #ESMOBreast24 where we’ll be hearing from leading #breastcancer experts live in Berlin 📝
Which talks are you excited to hear?
@myESMO #bcsm
April is #BowelCancer Awareness Month 📣
And we are passionate about bringing you the latest news & updates 🎥 🗞️
@AasmaShaukatMD, MD, MPH, discusses the current landscape of #colonoscopyscreening in the US 🇺🇸🔦
Learn more 👉 https://www.vjoncology.com/video/_sp7woohec8-colonoscopy-primary-screening-with-evolving-challenges/
#CRCsm
🎥@docchristoffer highlights the promising immunotherapeutic landscape for melanoma, discussing the INTerpath-001 trial's combinatory approach with neoantigen therapies and pembrolizumab:
➡️⬅️
#AACR24 #ImmunoOnc
INTerpath-001: individualized neoantigen vaccines with pembrolizumab in melanoma
Christoffer Gebhardt, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, summarizes the emerging immunotherape...
ow.ly
🎥@MarianaBrandao0 of @JulesBordet highlights the multifaceted considerations in defining operability for #NSCLC, shedding light on the challenges posed by stage III disease:
➡️⬅️
@BTOGORG #BTOG24 #LungCancer #LCSM
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao, MD, PhD, Institute Jules Bordet, Brussels, Belgium, delves into the complexities of defining operabilit...
ow.ly
ESMO Breast 2023
May is #BladderCancerAwarenessMonth 📣
@drenriquegrande discusses implications of the findings from the EV-302 trial (NCT04223856) of #enfortumab vedotin, an #ADC & #pembrolizumab in patients with locally advanced or metastatic #urothelialcancer 🔦
👉
Will enfortumab vedotin and pembrolizumab be the new SOC in urothelial cancer?
Enrique Grande, MD, PhD, MD Anderson Cancer Centre Madrid, Madrid, Spain, discusses the implications of the findings ...
ow.ly
We’re looking forward to #ESMOBreast24 where we’ll be hearing from leading #breastcancer experts live in Berlin 📝
Which talks are you excited to hear?
@myESMO #bcsm
April is #BowelCancer Awareness Month 📣
And we are passionate about bringing you the latest news & updates 🎥 🗞️
@AasmaShaukatMD, MD, MPH, discusses the current landscape of #colonoscopyscreening in the US 🇺🇸🔦
Learn more 👉 https://www.vjoncology.com/video/_sp7woohec8-colonoscopy-primary-screening-with-evolving-challenges/
#CRCsm
🎥@docchristoffer highlights the promising immunotherapeutic landscape for melanoma, discussing the INTerpath-001 trial's combinatory approach with neoantigen therapies and pembrolizumab:
➡️⬅️
#AACR24 #ImmunoOnc
INTerpath-001: individualized neoantigen vaccines with pembrolizumab in melanoma
Christoffer Gebhardt, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, summarizes the emerging immunotherape...
ow.ly
🎥@MarianaBrandao0 of @JulesBordet highlights the multifaceted considerations in defining operability for #NSCLC, shedding light on the challenges posed by stage III disease:
➡️⬅️
@BTOGORG #BTOG24 #LungCancer #LCSM
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao, MD, PhD, Institute Jules Bordet, Brussels, Belgium, delves into the complexities of defining operabilit...
ow.ly
